BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
MWN-AI** Summary
BeyondSpring Inc. (NASDAQ: BYSI) has published a pivotal human clinical study in "Med" (Cell Press) revealing that Plinabulin—a novel dendritic cell maturation agent—demonstrates promising efficacy in patients who have previously failed immune checkpoint inhibitors (ICIs). The study assessed Plinabulin in combination with radiation and PD-1 inhibitors across eight cancer types, delivering an overall response rate (ORR) of 23% and a disease control rate (DCR) of 54% in non-irradiated lesions.
Dr. Steven Lin, the study's corresponding author and a professor at The University of Texas MD Anderson Cancer Center, emphasized that the results indicate Plinabulin’s potential to reverse resistance to ICIs through dendritic cell maturation. Significant responses were notably observed in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, and Hodgkin lymphoma, with durable responses in heavily pre-treated Hodgkin lymphoma patients lasting over 19 months.
The analysis provided key biomarker insights, identifying the baseline GEF-H1 immune signature as a potential predictor of clinical response to Plinabulin. This finding could pave the way for pre-selecting patients likely to benefit from this treatment.
The study highlights an innovative strategy to reinvigorate immune responses in tumors that have proven resistant to existing therapies. BeyondSpring remains committed to advancing Plinabulin's development, in collaboration with leading cancer research institutions, with an eye on developing treatment plans that target a high unmet medical need in oncology.
As BeyondSpring continues its clinical journey, it could potentially redefine treatment paradigms for refractory cancers, illustrating the importance of adaptive and innovative approaches in cancer therapy.
MWN-AI** Analysis
BeyondSpring Inc. (NASDAQ: BYSI) has recently published promising results regarding Plinabulin’s efficacy in patients with tumors that have previously failed immune checkpoint inhibitor (ICI) therapy. The combination of Plinabulin, radiation, and PD-1 inhibitors showed an overall response rate (ORR) of 23% alongside a disease control rate (DCR) of 54% in non-irradiated lesions across multiple cancer types. This is particularly noteworthy given the substantial challenges associated with ICI resistance.
Investors should take note of BeyondSpring's strategic positioning in a highly competitive oncology market. The study highlights Plinabulin’s unique mechanism of action—stimulating dendritic cell (DC) maturation via GEF-H1 signaling—which may offer a valuable approach to treating patients whose cancers have become unresponsive to traditional therapies. The identification of the baseline GEF-H1 immune signature as a potential biomarker for patient pre-selection adds an additional layer of strategic opportunity, enabling more effective target identification.
The strong clinical signals, especially within non-small cell lung cancer (NSCLC) and Hodgkin lymphoma, underscore the potential for Plinabulin to provide much-needed alternatives in an area rife with unmet medical needs. Notably, the durability of responses seen, including some lasting over 19 months in heavily pre-treated patients, points to the possible long-term benefits of this treatment.
BeyondSpring plans to advance Plinabulin’s development in collaboration with leading research institutions, which could enhance its credibility and speed up the path to regulatory approval. With the momentum from this publication and positive clinical feedback, investors may want to consider increasing their positions in BeyondSpring. The company not only possesses a promising lead asset in Plinabulin but is also bolstered by its innovative RITE3™ platform through its subsidiary, SEED Therapeutics, creating a diversified portfolio with potential growth avenues. As such, BeyondSpring is positioned for promising long-term value creation amid rising interest in novel cancer therapies.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rate (ORR) of 23% and a disease control rate (DCR) of 54% in non-irradiated lesions.
- Biomarker analysis linked Plinabulin’s mechanism to GEF-H1–dependent dendritic cell maturation, offering the potential to pre-select patients at baseline and predict clinical response.
FLORHAM PARK, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) today announced publication of a human clinical study in Med (Cell Press) demonstrating that Plinabulin, when combined with radiation and a checkpoint inhibitor, induces dendritic cell (DC) maturation and elicits tumor responses in patients across multiple cancer types who had failed prior ICI therapy. The study also identified a potential biomarker—baseline GEF-H1 immune signature—that may enable patient pre-selection and clinical response prediction.
“These results offer early but important signals that Plinabulin’s dendritic cell maturation mechanism could play a pivotal role in reversing ICI-acquired resistance,” said Dr. Steven Lin, M.D., Ph.D., corresponding author and Professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center . “The ability of Plinabulin to activate the immune system in this setting is both scientifically intriguing and clinically promising—particularly given the durability of responses in some heavily pretreated patients.”
Dr. Lin added, “It is especially noteworthy that Plinabulin combination demonstrated the best responses in non-small cell lung cancer, head and neck squamous cell carcinoma, and Hodgkin lymphoma .”
“ This study builds upon the seminal work of Nobel Laureate Dr. Ralph Steinman and Dr. Ira Mellman, who helped define the essential role of dendritic cells in immune activation ,” said Lan Huang, Ph.D., Co-Founder, Chairman, and CEO of BeyondSpring . “Plinabulin’s ability to drive dendritic cell maturation and induce immune responsiveness offers a potential breakthrough strategy for patients who are refractory or relapsed on checkpoint inhibitors. We are committed to advancing Plinabulin’s development in partnership with pioneering cancer research institutions like MD Anderson.”
Triple I/O Combination Study Highlights
This investigator-initiated, Phase 1 translational trial (NCT04902040) evaluated a triple immunotherapy approach combining Plinabulin, radiation (RT), and anti-PD-1 checkpoint inhibitors in patients with eight cancer types who are refractory or relapsed on prior ICI therapy. RT was administered only during the first cycle. The primary endpoint was tumor response in non-irradiated lesions.
- Clinical Results
Nineteen patients received the combination regimen—14 on pembrolizumab and 5 on nivolumab. Tumor responses were evaluable in 13 ICI-relapsed patients across eight tumor types. Objective response rate (ORR) was 23%, and disease control rate (DCR) was 54% . Clinically meaningful benefits (PR, partial response; SD, stable disease) were observed in NSCLC (2/2), HNSCC (2/3), and Hodgkin lymphoma (2/2). Both Hodgkin lymphoma patients had durable responses exceeding 19 months despite 12–16 prior lines of therapy. - Mechanism Confirmation
Plinabulin triggered DC maturation post-RT via GEF-H1 signaling. Flow cytometry of whole blood revealed increased expression of DC maturation markers (CCR7, CD80, CD83) and a shift in monocyte subpopulations from classical to proinflammatory phenotype in responders. - Biomarker Insight
Single-cell RNA sequencing differentiated responders from non-responders and identified baseline GEF-H1 immune gene expression as a potential predictive biomarker for Plinabulin response.
About the Med Publication
Lin S.H., Subbiah V., Cohen E.N. et al. “Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers.” Med . Published June 27, 2025. ( https://www.cell.com/med/abstract/S2666-6340(25)00179-5 )
About the Plinabulin Basket Study
This open-label, single-arm Phase 1 basket study (NCT04902040) at MD Anderson Cancer Center investigates safety and efficacy of Plinabulin plus radiation and PD-1 inhibitor in patients refractory or relapsed after prior immunotherapy. The primary endpoint is investigator-assessed ORR (RECIST 1.1) in non-irradiated lesions; secondary endpoints include DCR.
- Regimen
– Radiation (Cycle 1 and optional Cycle 2): Local consolidative RT (8 Gy × 3; 12.5 Gy × 4; or 4 Gy × 5) on Day 1. Optional sequential RT in Cycle 2 at investigator discretion.
– Plinabulin: 30 mg/m² on Days 1 and 4 of Cycle 1 (3–6 hours post-RT); Day 1 of Cycle 2 onward; Additional Day 4 in Cycle 2 if RT is given in Cycle 2.
– PD-1 inhibitor: Pembrolizumab 200 mg on Day 1 every 21 days or nivolumab 240 mg on Day 1 every 14 days × 2 doses per cycle.
About Plinabulin
Plinabulin is a first-in-class dendritic cell maturation agent that binds reversibly to a unique site on tubulin, destabilizing microtubules in a controlled manner to release GEF-H1 (Chem 2019; Cell Reports 2019). Immune protein GEF-H1 activates the RhoA/ROCK signaling pathway, promoting dendritic cell maturation and anti-tumor T-cell immunity. This mechanism is distinct from traditional tubulin agents and does not interfere with tubulin stabilizers like docetaxel.
Across multiple clinical studies and approximately 800 patients , Plinabulin has shown durable anti-cancer activity and a favorable safety profile, and has significantly reduced chemotherapy-induced neutropenia, potentially enhancing docetaxel tolerability.
- Prior Findings:
– In the Dublin-3 Phase 3 second and third line (2/3L) NSCLC, EGFR wild-type trial (n=559), Plinabulin + docetaxel demonstrated a significant overall survival benefit over standard-of-care docetaxel (Lancet Respiratory Medicine 2024 - Press Release Link ).
– In a Phase 2 study of Plinabulin + pembrolizumab + docetaxel in 2/3L NSCLC who progressed on PD-1/L1 inhibitors (n=47), median PFS was 6.8 months, and 15-month OS rate was 78% (ASCO 2025 - Press Release Link ).
About BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and a range of cancer indications. Plinabulin’s novel mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation , offering a unique approach to resensitizing tumors to prior failure or progression to checkpoint inhibitors .
In addition, BeyondSpring is the founding equity holder of SEED Therapeutics, a biotechnology company pioneering targeted protein degradation (TPD) through the discovery of novel molecular glues and bifunctional degraders. Powered by its proprietary RITE3™ platform, SEED is advancing a pipeline of first-in-class degraders to address traditionally undruggable targets across oncology, neurodegeneration, immunology, and virology. SEED’s strategic collaborations with Eli Lilly and Company and Eisai Co., Ltd. support its mission to develop transformational therapies. Learn more at beyondspringpharma.com .
Investor Contact:
IR@beyondspringpharma.com
Media Contact:
PR@beyondspringpharma.com
FAQ**
Given the promising ORR of 23% and DCR of 54% in non-irradiated lesions for Plinabulin + radiation + PD-1 inhibitors, how does BeyondSpring Inc. BYSI plan to enhance these results in larger clinical trials?
What steps is BeyondSpring Inc. BYSI taking to validate the baseline GEF-H1 immune signature as a predictive biomarker for response to Plinabulin in future studies?
Considering the durable responses observed in Hodgkin lymphoma patients, how does BeyondSpring Inc. BYSI plan to prioritize ongoing research in this specific indication?
As Plinabulin aims to resensitize tumors to ICI therapy, what is BeyondSpring Inc. BYSI's strategy for collaboration with cancer research institutions to accelerate its development?
**MWN-AI FAQ is based on asking OpenAI questions about BeyondSpring Inc. (NASDAQ: BYSI).
NASDAQ: BYSI
BYSI Trading
6.29% G/L:
$1.69 Last:
26,335 Volume:
$1.65 Open:
